Table 2.
Clinical characteristics of subjects with proven/probable cured COVID-19 (Cohort 2) and comparisons between patients with detectable and undetectable IgGs; NA, not applicable.
| Patients with proven/probable cured COVID-19 | |||
|---|---|---|---|
| Overall | IgG-positive patients | IgG-negative patients | |
| Median age, in years (IQ range) | 49 (36.25–55) | 50 (36.7–55.2) | 40 (34–55.5) |
| Male | 16 (40%) | 13 (43.3%) | 3 (30%) |
| Presence of symptoms | 40 (100%) | 30 (100%) | 10 (100%) |
| Days from onset of symptoms to serum sampling (IQ range) | 26 (22–32) | 26 (22.5–31.5) | 26.5 (19.5–32.5) |
| Fever (> 38 °C) | 19 (47.5%) | 16 (53.3%) | 3 (30%) |
| Headache | 31 (77.5) | 21 (70%) | 10 (100%) |
| Cough | 23 (57.5) | 19 (63.3%) | 4 (40%) |
| Asthenia | 25 (62.5) | 19 (63.3%) | 6 (60%) |
| Myalgia | 30 (75%) | 22 (73.3%) | 8 (80%) |
| Sore throat | 11 (27.5%) | 20 (33.3%) | 1 (10%) |
| Runny nose | 13 (32.5%) | 12 (40%) | 1 (10%) |
| Dyspnoea | 16 (40%) | 12 (40%) | 4 (40%) |
| Pneumonia | 13 (32.5%) | 10 (33.3%) | 3 (30%)* |
| Anosmia | 18 (45%) | 17 (56.7%) | 1 (10%) |
| Ageusia | 17 (42.5%) | 15 (50%) | 2 (20%) |
| Abdominal pain | 5 (12.5%) | 5 (16.7%) | 0 (0%) |
| Diarrhoea | 10 (25%) | 8 (26.7%) | 2 (20%) |
| Hospital admission | 1 (2.5%) | 1 (3.3) | 0 (0%) |
| Death | 0 (0%) | 0 (0%) | 0 (0%) |
| Positive IgG determination | 30 (75%) | NA | NA |
| No. of patients | 40 | 30 | 10 |
Numbers in bold indicate differences reaching statistical significance (P < 0.05). *Chest X-rays were performed in 22 out of the 40 patients.